摘要
目的观察华蟾素注射液配合吉西他滨与顺铂治疗非小细胞肺癌(NSCLC)的临床疗效。方法将217例NSCLC患者随机分为治疗组109例和对照组108例,对照组治疗第1、8天予吉西他滨1000mg/m2静脉滴注,顺铂80～100mg/m2分2～3天静脉滴注;治疗组在对照组的基础上静脉滴注华蟾素20ml。28天为1个周期,治疗3个周期后对临床疗效、受益率、生存率、肿瘤进展时间、生活质量以及不良反应进行评估。结果治疗组与对照组的有效率分别为55.96%和37.96%,两组比较差异有统计学意义(P<0.05);治疗组和对照组的中位肿瘤进展分别为30周和24周,差异有统计学意义(P<0.05);与对照组比较,治疗组患者6个月、1年、2年的生存率明显上升(P<0.05)。两组治疗后患者生活质量评分明显提高(P<0.05),但治疗后治疗组和对照组比较差异无统计学意义(P>0.05)。与对照组比较,治疗组不良反应发生率明显下降(P<0.05)。结论华蟾素注射液配合吉西他滨与顺铂疗法有助于NSCLC患者临床症状的改善和临床疗效、生活质量的提高。
Objective To evaluate the effect of cinobutacini injection plus gemcitabine and cisplatin on non-small cell lung cancer （NSCLC）. Methods A total of 217 NSCLC patients were randomized into treatment group, 109 cases, and control group, 108 cases. The control group was treated with cinobutacini 1000mg/m2 on the first and 8th day; cisplatin 80-100mg/ mS on the second and the third day; based on which, the treatment group was treated with cinobutaeini injection 20ml via intra- venous drip. One period of treatment was of 28 days. After 3 periods of treatment, the therapeutic effect, benefit rate, survival rate, time of tumor progression, quality of life, and adverse reactions were evaluated. Results The effective rate of the treatment group and the control group was 55. 96% and 37.96% respectively, the difference between the two groups was statistically significant （P〈0.05）. The median tumor progression of the treatment group and control group was 30 weeks and 24 weeks respectively, and the statistical difference was found between groups （P〈0.05）. Compared with the control group, the survival rate of the treatment group in six months, one year, and two years was increased significantly with statistical difference （P〈0.05）. In comparing respectively with before treatment, the quality of life of both groups was significantly improved （P〈0.05）, but the comparison between the two groups after treatment showed no statistical difference （P〈0.05）. To compare with the control group, the adverse reactions of the treatment group were significantly decreased （P〈0.05）. Conclusion The einobutacini injection plus gemcitabine and cisplatin is helpful in alleviating clinical symptoms and improving life quality of NSCLC patients.
出处
《中医杂志》
CSCD
北大核心
2011年第24期2115-2118,共4页
Journal of Traditional Chinese Medicine
关键词
华蟾素
吉西他滨
顺铂
非小细胞肺癌
生存率
生活质量
cinobutacini
gemcitabine
cisplatin
non-small cell lung cancer （NSCLC）
survival rate
quality of life
